{"id":690248,"date":"2024-03-05T09:28:01","date_gmt":"2024-03-05T09:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=690248"},"modified":"2024-03-05T09:28:01","modified_gmt":"2024-03-05T09:28:01","slug":"migraine-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-amgen-teva-pharmaceuticals-eli-lilly-and-company-anne-lindblad-allergan-abbvie","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/migraine-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-amgen-teva-pharmaceuticals-eli-lilly-and-company-anne-lindblad-allergan-abbvie_690248.html","title":{"rendered":"Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1709547365.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie\" src=\"https:\/\/www.abnewswire.com\/uploads\/1709547365.jpeg\" alt=\"Migraine Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, AbbVie\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cMigraine Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the 7MM.<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;Migraine Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong> report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Migraine Market Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Migraine Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Migraine market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period (2019-2032)<\/li>\n<li>All participants who had a headache within the previous 12 months prior to the survey between October 2019 and March 2020 were included in the BURDEN 2020 study, which was developed by the RKI and conducted by the market and social research institute USUMA GmbH. According to the survey, 40.4% of men and 57.5% of women reported having headaches in the previous 12 months. In both men and women, 6.0% and 1.2%, respectively, suffered from migraines<\/li>\n<li>Migraine is the most prevalent neurological condition, according to German research community funding headache research in Essen 2021. Around <strong>14% of German<\/strong> women and <strong>8% of German<\/strong> men are affected. About 2% of people have a chronic form of the condition<\/li>\n<li><strong>Key Migraine Companies:<\/strong> Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A\/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others<\/li>\n<li><strong>Key Migraine Therapies:<\/strong> AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others<\/li>\n<li>The Migraine epidemiology based on gender analyzed that the prevalence of migraine in female is slightly higher than male<\/li>\n<li>The Migraine market is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Migraine Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Migraine, a main headache illness, is a neurological condition that commonly manifests as severe, incapacitating headaches among other symptoms. It affects all ages and frequently runs in families. There are primarily two types: acute migraine and Migraine.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the Migraine Market Report&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/migraine-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/migraine-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Migraine Epidemiology<\/strong><\/p>\n<p style=\"text-align: justify;\">The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Migraine Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Migraine market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Migraine<\/li>\n<li>Prevalent Cases of Migraine by severity<\/li>\n<li>Gender-specific Prevalence of Migraine<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Migraine<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Migraine epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/migraine-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Migraine Epidemiology Forecast<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Migraine Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n<p style=\"text-align: justify;\">The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n<p style=\"text-align: justify;\">The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Migraine Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>AIMOVIG:<\/strong> Amgen<\/li>\n<li><strong>Fremanezumab:<\/strong> Teva Pharmaceuticals<\/li>\n<li><strong>Galcanezumab:<\/strong> Eli Lilly and Company<\/li>\n<li><strong>propranolol LA:<\/strong> Anne Lindblad<\/li>\n<li><strong>Atogepant:<\/strong> Allergan<\/li>\n<li><strong>LBR-101:<\/strong> Teva Branded Pharmaceutical<\/li>\n<li><strong>Atogepant:<\/strong> AbbVie<\/li>\n<li><strong>Galcanezumab:<\/strong> Eli Lilly and Company<\/li>\n<li><strong>Marcaine:<\/strong> Tian Medical Inc.<\/li>\n<li><strong>Atogepant: <\/strong>Allergan<\/li>\n<li><strong>Galcanezumab:<\/strong> Eli Lilly and Company<\/li>\n<li><strong>Eptinezumab:<\/strong> H. Lundbeck A\/S<\/li>\n<li><strong>TNX-1900:<\/strong> Tonix Pharmaceuticals, Inc.<\/li>\n<li><strong>IONIS-PKKRx (ISIS 546254):<\/strong> Ionis Pharmaceuticals, Inc.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Migraine market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/migraine-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Migraine Treatment Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Migraine Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Migraine Companies:<\/strong> Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A\/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others<\/li>\n<li><strong>Key Migraine Therapies:<\/strong> AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others<\/li>\n<li><strong>Migraine Therapeutic Assessment:<\/strong> Migraine current marketed and Migraine emerging therapies<\/li>\n<li><strong>Migraine Market Dynamics:<\/strong> Migraine market drivers and Migraine market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li>M<strong>igraine Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Migraine Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Migraine companies working in the treatment market, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/migraine-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Migraine Clinical Trials and Therapeutic Assessment<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Migraine Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Migraine<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Migraine<\/p>\n<p style=\"text-align: justify;\">4. Migraine Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Migraine Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Migraine Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Migraine Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Migraine&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Migraine Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Migraine Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Migraine Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Migraine Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Migraine Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Migraine Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Migraine Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Migraine Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Migraine Appendix<\/p>\n<p style=\"text-align: justify;\">18. Migraine Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\">It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_72253.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=migraine-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-amgen-teva-pharmaceuticals-eli-lilly-and-company-anne-lindblad-allergan-abbvie\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=migraine-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-amgen-teva-pharmaceuticals-eli-lilly-and-company-anne-lindblad-allergan-abbvie\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>\u201cMigraine Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the 7MM. DelveInsight&rsquo;s &ldquo;Migraine Market Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/migraine-market-to-exhibit-rapid-growth-rate-during-the-forecast-period-20232032-investigates-delveinsight-amgen-teva-pharmaceuticals-eli-lilly-and-company-anne-lindblad-allergan-abbvie_690248.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-690248","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=690248"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/690248\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=690248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=690248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=690248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}